Nathan Staff is a Neurology physician affiliated with Mayo Clinic. OpenAlex indexes 194 publications with 7,478 citations (h-index 40); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 1st St SW
Rochester, MN 559050001
Telephone
507-284-2511Provider last certified this registry record 20 Aug 2020.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Organon LLCProgram year20251 payment
- ARGENX US, INC.Program year20241 payment
- MITSUBISHI TANABE PHARMA AMERICA, INC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
5 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity
Mayo Clinic Rochester
FY2026$622,064R01CA275870 - Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity
Mayo Clinic Rochester
FY2025$622,064R01CA275870
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Mis-spliced transcripts generate de novo proteins in TDP-43–related ALS/FTD
Science Translational Medicine
2024 - Mis-spliced transcripts generate <i>de novo</i> proteins in TDP-43-related ALS/FTD
bioRxiv (Cold Spring Harbor Laboratory)
2023 - MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis in a Phase IIb/III Study: COMBAT-ALS Study Design
Neurodegenerative Disease Management
2021
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”